1064P - High-Dose versus Low-Dose Cisplatin With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck (SCC): An Analysis of...

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cytotoxic agents
Cancers in Adolescents and Young Adults (AYA)
Head and Neck Cancers
Surgical oncology
Biological therapy
Radiation oncology
Presenter Joshua Bauml
Citation Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374
Authors J. Bauml1, R. Vinnakota2, Y.A. Park3, S.E. Bates2, T. Fojo2, C. Aggarwal4, S. Lunate3, N. Damjanov1, R. Mamtani4, C.J. Langer4, R.B. Cohen4, K. Sigel5
  • 1Hematology/oncology, Corporal Michael J Crescenz VA Medical Center, 19104 - Philadelphia/US
  • 2Hematology/oncology, Columbia University Medical Center, 10032 - New York/US
  • 3Hematology/oncology, James J Peters VA Medical Center, 10468 - New York/US
  • 4Hematology/oncology, Perelman School of Medicine at the University of Pennsylvania, 19104 - Philadelphia/US
  • 5Infectious Diseases, James J Peters VA Medical Center, 10468 - New York/US



Radiotherapy (RT) with concurrent high-dose cisplatin (HDC) improves outcomes for patients (pts) with SCC. Weekly low-dose cisplatin (LDC) is a widely used alternative approach. The comparative effectiveness and safety of these approaches is unknown. We compared the outcomes of pts treated with HDC and LDC within the Veteran’s Administration Corporate Data Warehouse (CDW).


We identified stage III-IVb SCC patients treated non-surgically with RT and HDC or LDC from 2002 to 2014 in the CDW. Pts were grouped by the dose of their first cycle (HDC vs LDC; intent-to-treat). Variables including cancer site, stage, smoking/alcohol use, and comorbidities were used to generate propensity scores (PS) for the use of HDC. We compared overall survival (OS) by treatment group using Cox regression models, adjusting for PS. We also determined the risk of toxicities using PS-adjusted logistic regression models.


A total of 2,820 pts were included in the analysis: 69.7% received HDC (mean initial dose 96 mg/m2). The mean initial dose of LDC was 30 mg/m2. HDC pts were younger (p 


While HDC does not improve OS over LDC for the overall cohort of patients with SCC receiving RT with definitive intent, it is associated with a survival benefit for patients with OP. HDC is associated with more adverse events.

Clinical trial identification


Legal entity responsible for the study

Keith Sigel




J. Bauml: Research Support: Merck, Bayer, Novartis, Carevive Systems Consulting: Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Celgene, Genentech, Merck, Guardant Health. C. Aggarwal: Roche, Bristol-Myers Squibb, Eli Lilly: Ad boards Takeda, Macrogenics, Roche: Research support to institution. C.J. Langer: Research: Pfizer, Lilly, Genentech, OSI; GSK; Clovis; Merck; Nektar; Advantagene; Inovio; Takeda; AbbVie Advisor: Bristol-Myers Squibb, ImClone, Pfizer, Lilly; AstraZeneca; Merck; Novartis; Genentech; Bayer; Celgene; Abbott; Biodesix; Clariant; Caris; ARIAD; Boehringer Ingelheim; Synta; Clovis; Amgen; Synta; Peregrine; Incyte. R.B. Cohen: Takeda scientific ad board Zymeworks, Bristol-Myers Squibb. All other authors have declared no conflicts of interest.